Table 1.
Antiviral activity of BPR1P0034.
| Concentration (μM) | ||||
|---|---|---|---|---|
| BPR1P0034 | Amantadine | Zanamivir | ||
| IC50 | CC50c | IC50 | IC50 | |
| Cytotoxic effect | ||||
| MDCK | 6.75 ± 0.08 | |||
| Influenza virus | ||||
| A/WSN/33 (H1N1)b | 0.21 ± 0.07 | > 25 | 0.06 ± 0.02 | |
| A/Udorn/72 (H3N2)a | 2.11 ± 0.41 | 0.98 ± 0.15 | 0.67 ± 0.23 | |
| A/TW/83/05 (H3N2)a | 1.38 ± 0.08 | > 25 | 0.92 ± 0.03 | |
| A/TW/785/05 (H1N1)a | 0.92 ± 0.11 | 0.38 ± 0.24 | 1.06 ± 0.98 | |
| B/TW/710/05b | 8.11 ± 3.98 | > 25 | 0.03 ± 0.02 | |
| B/TW/70325/05b | 1.94 ± 0.72 | > 25 | 0.02 ± 0.01 | |
| B/TW/99/07b | 8.90 ± 4.16 | > 25 | 0.10 ± 0.01 | |
| Enterovirus 71b | ||||
| TW/1743/98 | > 40 | > 20 | -- | -- |
| TW/4643/98 | > 20 | > 20 | -- | -- |
| Echovirus 9b | > 20 | > 20 | -- | -- |
MDCK cells or Vero cells were infected with influenza virus and EV71, respectively, and incubated with different concentrations of BPR1P0034.
IC50was determined with a plaque reduction assaya or a neutralization assayb
cCC50 was determined with an MTT assay
--, not determined
The values are means ± SD of 2--3 independent experiments.